Scientists test 'Living Drug' made from Patients' own tumors to fight rare cancers
NCT ID NCT05607095
Summary
This early-stage study is testing a personalized treatment called lifileucel for patients with advanced uveal melanoma (a rare eye cancer) or certain aggressive soft-tissue sarcomas. Doctors take a patient's own immune cells from their tumor, grow large numbers of them in a lab, and then infuse them back into the patient to attack the cancer. The main goal of this initial study is to check the safety of this complex treatment process.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Memorial Sloan Kettering Cancer Center (All Protocol Activities)
RECRUITINGNew York, New York, 10065, United States
Contact Phone: •••-•••-••••
-
Memorial Sloan Kettering Westchester
RECRUITINGHarrison, New York, 10604, United States
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.